LivaNova PLC (LIVN) slipped over 11% on Thursday morning after a clinical study evaluating VNS therapy for treatment-resistant depression in unipolar patients failed to meet primary endpoints.
LIVN is currently trading at $53.11, down $6.92 or 11.52%, on the Nasdaq. The stock opened its trading at $52.35 after closing Wednesday at $60.03. The stock has traded between $42.75 and $64.47 in the past 52-week period.
LivaNova announced the preliminary results for the unipolar patient cohort of the RECOVER clinical study, assessing the use of VNS Therapy in treatment-resistant depression. The study did not meet its primary endpoint (PE) for the unipolar cohort; however, statistical significance was achieved in select secondary endpoints.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.